s6y

Quoin Pharmaceuticals Ltd.

Ticker
QNRX
CIK
1671502
Industry
Pharmaceutical Preparations
Formerly
Quoin Pharmaceuticals, Ltd., Cellect Biotechnology Ltd., Cellect Biomed Ltd.

Financials 16

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 16 financials filings

News 68

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 68 news filings

Ownership 97

  1. 4/A Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 97 ownership filings

Prospectus 83

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-3 Registration statement for specified transactions by certain issuers
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. S-3 Registration statement for specified transactions by certain issuers
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 83 prospectus filings

Proxies 14

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  9. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  10. DEF 14A Definitive proxy statements

All 14 proxies filings

Other 309

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G
  3. EFFECT Notice of Effectiveness
  4. SCHEDULE 13G/A
  5. EFFECT Notice of Effectiveness
  6. D Exempt (Private) Offering
  7. ARS Annual report to security holders
  8. SCHEDULE 13G
  9. SCHEDULE 13G/A
  10. SCHEDULE 13G/A

All 309 other filings